[Anticoagulation for plasmapheresis].
Amemiya
Hitoshi
H
Department of Clinical Engineering, Showa University Fujigaoka Hospital.
Sekihara
Hiroyuki
H
Kobayashi
Tutomu
T
Koiwa
Fumihiko
F
Niikura
Kazuhiko
K
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001550:Benzamidines; D002951:Citrates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006146:Guanidines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D008991:Monitoring, Physiologic; D010956:Plasmapheresis / Q000379:methods*; D000077559:Sodium Citrate; D014914:Whole Blood Coagulation Time
D000925:Anticoagulants; D001550:Benzamidines; D002951:Citrates; D006146:Guanidines; D006495:Heparin, Low-Molecular-Weight; D000077559:Sodium Citrate; D006493:Heparin; C032855:nafamostat